Physician profile

Joseph Vaydovsky

Obstetrics & Gynecology · Perth Amboy, NJ

NPI 1609800564

$2,489.76

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$62.13
Consulting Fee$25.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ethicon INC. $2,265.48 2019-2020
Medtronic, INC. $50.00 2021-2024
Abbvie INC. $42.03 2021
Merck Sharp & Dohme LLC $29.55 2022-2023 Verquvo
Boston Scientific Corporation $25.42 2022
Coopersurgical, INC. $18.00 2024 Paragard T 380a
Organon LLC $16.83 2023 Nexplanon
Mylan Pharmaceuticals INC. $16.28 2022
Hologic Sales and Service, LLC $13.42 2020
Ethicon US, LLC $12.75 2023 Stratafix

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joseph Vaydovsky

$2,489.76

in general payments reported 2019-2025

Years
2019-2024
Top company
Ethicon INC.

https://glasscript.com/doctor/344591/joseph-vaydovsky

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.